Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma Chi-Fu Jeffrey Yang, MD, Hanghang Wang, MD, PhD, Arvind.

Slides:

Advertisements

Similar presentations

Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.

Advertisements

Adjuvant Radiation is Not Associated with Improved Survival in Patients with Positive Margins Following Lobectomy for Stage I & II Non-Small Cell Lung.

Date of download: 7/2/2016 From: An Acute Change in Lung Allocation Score and Survival After Lung Transplantation: A Cohort Study Ann Intern Med. 2013;158(9):

Treatment of Stage I and II Non-small Cell Lung Cancer

A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer Babatunde A. Yerokun, MD, Chi-Fu.

Volume 105, Issue 3, Pages (March 1994)

ICU Telemedicine Program Financial Outcomes

Outcomes of Nurse Practitioner-Delivered Critical Care

Clinical and Personality Profiles and Survival in Patients With COPD

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

A 51-Year-Old Woman With an Increasing Chest Wall Mass Years After Resection of an Early Stage Lung Cancer Ajay Dhakal, MBBS, Hongbin Chen, MD, PhD,

Hospital Volume and Outcomes of Robot-Assisted Lobectomies

Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Nathan M. Mollberg, DO,

Jianqiao Cai, MD, Jian Zhou, MD, Fan Yang, MD, Jun Wang, MD CHEST

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

Diagnostic Surgical Pathology in Lung Cancer

Do tumor location and grade affect survival in pT2N0M0 esophageal squamous cell carcinoma? Dongrong Situ, MD, Junye Wang, MD, PhD, Peng Lin, MD, PhD,

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Treatment of Stage I and II Non-small Cell Lung Cancer

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Precision Medicine Urgency

Surgical quality of wedge resection affects overall survival in patients with early stage non–small cell lung cancer Gaurav S. Ajmani, MHS, Chi-Hsiung.

Chi-Fu Jeffrey Yang, MD, Derek Y. Chan, BSE, Paul J

Nirav S. Kapadia, MD, MS, Luca F. Valle, MD, Julie A

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Treatment of Stage IV Non-small Cell Lung Cancer

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer

Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non- Small Cell Lung Cancer Paul J. Speicher, MD, Zachary W. Fitch,

Joshua E. Rosen, BASc, Michelle C

Weekday and Survival After Pulmonary Resections for Lung Cancer

Relationship Between Tumor Size and Survival in Non–Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER)

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Minimally Invasive Versus Open Esophagectomy for Esophageal Cancer: A Population- Based Analysis Babatunde A. Yerokun, MD, Zhifei Sun, MD, Chi-Fu Jeffrey.

A Risk Score to Assist Selecting Lobectomy Versus Sublobar Resection for Early Stage Non-Small Cell Lung Cancer Brian C. Gulack, MD, Chi-Fu Jeffrey Yang,

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Imaging for the Management of Community-Acquired Pneumonia

Treatment of Stage I and II Non-small Cell Lung Cancer

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer Usman Ahmad, MD, Traves D. Crabtree,

Conditional Cancer-Specific Versus Cardiovascular-Specific Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Shawn S. Groth, MD, MS, Natasha.

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Photodynamic Therapy for Early Stage Central Type of Lung Cancer

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Improved Lymph Node Staging in Early-Stage Lung Cancer in the National Cancer Database Seth B. Krantz, MD, Waseem Lutfi, BS, Kristine Kuchta, MS, Chi-Hsiung.

The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis Pamela Samson, MD, Aalok Patel, BS,

The National Surgical Quality Improvement Program risk calculator does not adequately stratify risk for patients with clinical stage I non–small cell.

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy Todd.

Volume 150, Issue 1, Pages (July 2016)

Kshitij Chatterjee, MD, Abhinav Goyal, MD, Manish Joshi, MD CHEST

Volume 155, Issue 1, Pages (January 2019)

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Variation in Hospital Adoption Rates of Video-Assisted Thoracoscopic Lobectomy for Lung Cancer and the Effect on Outcomes Zaid M. Abdelsattar, MD, MS,

Patient Preferences in Treatment Choices for Early-Stage Lung Cancer

The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients

Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care Richard F. Riedel, MD, Xiaofei Wang, PhD, Meg McCormack, PA-C, Eric Toloza,

Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Mark F. Berry, MD, Chi-Fu Jeffrey.

Should Large Cell Neuroendocrine Lung Carcinoma be Classified and Treated as a Small Cell Lung Cancer or with Other Large Cell Carcinomas? John M. Varlotto,

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Carcinoma of the esophagus: Prognostic significance of histologic type

Volume 115, Issue 6, Pages (June 1999)

Thoracic Surgery Survey on Lung Cancer Management

Neal S Goldstein, MD The Annals of Thoracic Surgery

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma Chi-Fu Jeffrey Yang, MD, Hanghang Wang, MD, PhD, Arvind Kumar, BS, Xiaofei Wang, PhD, Matthew G. Hartwig, MD, MHS, Thomas A. D'Amico, MD, Mark F. Berry, MD, MHS CHEST DOI: 10.1016/j.chest.2017.07.032 Copyright © 2017 American College of Chest Physicians Terms and Conditions

Figure 1 Diagram showing schema of study subject selection. NSCLC = non-small cell lung cancer. CHEST DOI: (10.1016/j.chest.2017.07.032) Copyright © 2017 American College of Chest Physicians Terms and Conditions

Figure 2 A, Overall survival of clinical stage IA NSCLC patients with squamous cell carcinoma undergoing lobectomy. Represents overall survival of all patients, regardless of the number of days between diagnosis and surgery. B, Overall survival of clinical stage IA NSCLC patients with squamous cell carcinoma stratified by early vs late timing to lobectomy. Survival is calculated from date of diagnosis. Patients who received lobectomy within 37 days after diagnosis were classified as having “early” lobectomy, whereas those who received surgery starting on day 38 were classified as receiving “late” lobectomy. C, Overall survival of clinical stage IA NSCLC patients with squamous cell carcinoma stratified by early vs late timing to lobectomy. Overall survival is calculated from date of definitive surgery. Patients who received lobectomy within 37 days after diagnosis were classified as having “early” lobectomy, whereas those who received surgery starting on day 38 were classified as receiving “late” lobectomy. D, Overall survival of clinical stage IA NSCLC patients with squamous cell carcinoma stratified by early vs late timing to lobectomy. Overall survival is calculated from four months after date of diagnosis. Patients who received lobectomy within 37 days after diagnosis were classified as having “early” lobectomy while those who received surgery starting on day 38 were classified as receiving “late” lobectomy. See Figure 1 legend for expansion of abbreviation. CHEST DOI: (10.1016/j.chest.2017.07.032) Copyright © 2017 American College of Chest Physicians Terms and Conditions

Figure 3 Relationship between timing to lobectomy and overall survival for patients with clinical stage IA NSCLC diagnosed with squamous cell carcinoma. Spline plots for adjusted Cox models excluding patients who underwent surgery on the day of diagnosis for A, men, B, women, C, the entire cohort, and D, the entire cohort including patients who underwent surgery on the day of diagnosis. Median values for all covariates are used as reference standard. Model was adjusted for age, race, Charlson/Deyo comorbidity score, insurance type, tumor size, facility type, distance from patient’s residence to hospital, median household income, and hospital volume. Red area indicates 95% CI. See Figure 1 legend for expansion of abbreviation. CHEST DOI: (10.1016/j.chest.2017.07.032) Copyright © 2017 American College of Chest Physicians Terms and Conditions